RU2019131542A - Соединения, связывающие AMHRII, для профилактики или лечения раковых заболеваний легкого - Google Patents
Соединения, связывающие AMHRII, для профилактики или лечения раковых заболеваний легкого Download PDFInfo
- Publication number
- RU2019131542A RU2019131542A RU2019131542A RU2019131542A RU2019131542A RU 2019131542 A RU2019131542 A RU 2019131542A RU 2019131542 A RU2019131542 A RU 2019131542A RU 2019131542 A RU2019131542 A RU 2019131542A RU 2019131542 A RU2019131542 A RU 2019131542A
- Authority
- RU
- Russia
- Prior art keywords
- amhrii
- binding agent
- chain containing
- containing seq
- amhrii binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
Claims (20)
1. Применение агента, связывающего AMHRII (рецептор антимюллеровского гормона типа II) человека, в качестве активного ингредиента для предотвращения или лечения рака легкого у пациента, страдающего от рака легкого, выбранного из группы, состоящей из эпидермоидного немелкоклеточного рака легкого (NSCLC), аденокарциномы NSCLC, крупноклеточного NSCLC, плоскоклеточной карциномы NSCLC, плеоморфной карциномы NSCLC и нейроэндокринного NSCLC.
2. Применение по п. 1, где агент, связывающий AMHRII человека, выбран из группы, состоящей из моноклонального антитела к AMHRII и его AMHRII-связывающих фрагментов.
3. Применение по п. 1 или 2, где агент, связывающий AMHRII человека, представляет собой моноклональное антитело, выбранное из группы, состоящей из следующих антител:
а) легкая цепь, содержащая SEQ ID NO: 2, и тяжелая цепь, содержащая SEQ ID NO: 4 (безлидерные последовательности VL и VH 3C23);
b) легкая цепь, содержащая SEQ ID NO: 6, и тяжелая цепь, содержащая SEQ ID NO: 8 (безлидерные последовательности VL и VH 3C23K);
c) легкая цепь, содержащая SEQ ID NO: 10, и тяжелая цепь, содержащая SEQ ID NO: 12 (безлидерные легкая и тяжелая цепи 3C23);
d) легкая цепь, содержащая SEQ ID NO: 14, и тяжелая цепь, содержащая SEQ ID NO: 16 (безлидерные легкая и тяжелая цепи 3C23K).
4. Применение по п. 1, где агент, связывающий AMHRII человека, представляет собой моноклональное антитело, содержащее CDR, содержащие следующие последовательности:
- CDRL-1: RASX1X2VX3X4X5A, где Xi и X2 независимо представляют собой S или P, X3 представляет собой R, или W, или G, X4 представляет собой T или D, и X5 представляет собой I или T;
- CDRL-2 представляет собой PTSSLX6S, где X6 представляет собой K или E; и
- CDRL-3 представляет собой LQWSSYPWT;
- CDRH-1 представляет собой KASGYX7FTX8X9HIH, где X7 представляет собой S или T, X8 представляет собой S или G, и X9 представляет собой Y или N;
- CDRH-2 представляет собой WIYPX10DDSTKYSQKFQG, где Xw представляет собой G или E; и
- CDRH-3 представляет собой GDRFAY.
5. Применение по любому из пп. 1-4, где агент, связывающий AMHRII человека, состоит из конъюгата антитело-лекарственное средство (ADC).
6. Применение по п. 1, где агент, связывающий AMHRII человека, представляет собой сконструированный AMHRII-связывающий рецептор.
7. Применение по п. 1, где агент, связывающий AMHRII человека, представляет собой клетку, экспрессирующую сконструированный AMHRII-связывающий рецептор.
8. Применение по п. 7, где агент, связывающий AMHRII человека, представляет собой CAR (химерный рецептор антигена)-T-клетку, CAR-NK (естественный киллер)-клетку или CAR-макрофаг, экспрессирующие сконструированный AMHRII-связывающий рецептор.
9. Применение по любому из пп. 1-8, где указанный агент, связывающий AMHRII человека, находится в комбинации с одним или более отдельным(-и) противораковым(-и) агентом(-ами).
10. Способ определения наличия ответной реакции индивидуума, страдающего от рака легкого, на лечение рака с помощью агента, связывающего AMHRII, как определено в любом из пп. 1-8, где указанный способ включает стадию определения наличия экспрессии образцом опухолевой ткани, предварительно полученным от указанного индивидуума, белка AMHRII на поверхности клетки.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305446 | 2017-04-14 | ||
EP17305446.1 | 2017-04-14 | ||
PCT/EP2018/059553 WO2018189381A1 (en) | 2017-04-14 | 2018-04-13 | Amhrii-binding compounds for preventing or treating lung cancers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2023114565A Division RU2023114565A (ru) | 2017-04-14 | 2018-04-13 | Соединения, связывающие AMHRII, для профилактики или лечения раковых заболеваний легкого |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019131542A true RU2019131542A (ru) | 2021-05-14 |
RU2019131542A3 RU2019131542A3 (ru) | 2021-08-18 |
RU2797506C2 RU2797506C2 (ru) | 2023-06-06 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
US20230227566A1 (en) | 2023-07-20 |
JP7289420B2 (ja) | 2023-06-12 |
CN110944665A (zh) | 2020-03-31 |
JP2020516655A (ja) | 2020-06-11 |
WO2018189381A1 (en) | 2018-10-18 |
EP3609919A1 (en) | 2020-02-19 |
MX2019012136A (es) | 2020-07-20 |
BR112019021495A2 (pt) | 2020-05-12 |
CA3058541A1 (en) | 2018-10-18 |
BR112019021495A8 (pt) | 2023-05-02 |
JP7289420B6 (ja) | 2023-06-30 |
KR20200014277A (ko) | 2020-02-10 |
RU2019131542A3 (ru) | 2021-08-18 |
CN110944665B (zh) | 2024-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
JP2018508475A5 (ru) | ||
FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
RU2012117619A (ru) | ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3 | |
RU2019120400A (ru) | Композиции и способы, связанные с клеточными системами для проникновения в солидные опухоли | |
RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
RU2017116847A (ru) | Антитела к pd-1 | |
RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
JP2018502051A5 (ru) | ||
JP2018534933A5 (ru) | ||
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
RU2012137502A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2012137504A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
JP2007536932A5 (ru) | ||
RU2014138474A (ru) | Новые модуляторы и способы применения | |
JP2020516655A5 (ru) | ||
EA201070888A1 (ru) | Антитела и их производные | |
RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
JP2015508063A5 (ru) |